Skip to content
Aulos Bioscience logo

Aulos Bioscience Alternatives & Competitors

12 companies similar to Aulos Bioscience — We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct t...

Companies similar to Aulos Bioscience

Merus N.V. logo — alternative to Aulos Bioscience

Merus N.V.

Merus was acquired by Genmab. To see what’s new, visit Genmab.

Surface Oncology Inc. logo — alternative to Aulos Bioscience

Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2...

ImmunoBiochem Corporation logo — alternative to Aulos Bioscience

ImmunoBiochem Corporation

Improving patient outcomes through innovations in biological therapeutics

Oxford BioTherapeutics logo — alternative to Aulos Bioscience

Oxford BioTherapeutics

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

Rival Readout

Competing with Aulos Bioscience? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Elevation Oncology logo — alternative to Aulos Bioscience

Elevation Oncology

We are focused on discovering and developing selective cancer therapies to treat patients...

Tradewind BioScience logo — alternative to Aulos Bioscience

Tradewind BioScience

Innovative therapeutics for the most aggressive cancers

Harpoon Therapeutics logo — alternative to Aulos Bioscience

Harpoon Therapeutics

SPEARHEADING IMMUNOTHERAPIES

DEM Biopharma, Inc. logo — alternative to Aulos Bioscience

DEM Biopharma, Inc.

Novel Target for Solid Tumors

ImmunoGenesis, Inc. logo — alternative to Aulos Bioscience

ImmunoGenesis, Inc.

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...

Apexigen logo — alternative to Aulos Bioscience

Apexigen

Creating Transformative Immunotherapies for Patients with Cancer

OncoResponse logo — alternative to Aulos Bioscience

OncoResponse

Interrogating for Cures

Cytovation logo — alternative to Aulos Bioscience

Cytovation

Creating transformative medicines for patients with cancer

About Aulos Bioscience

Aulos Bioscience is an immuno-oncology company that aims to revolutionize cancer patient care through its computationally designed IL-2 therapeutics. The company's flagship clinical candidate, AU-007, has been engineered to leverage a patient's own IL-2 to induce tumor killing while minimizing associated toxicities. Fo...

Business keywords

Immuno-oncology, IL-2 Therapeutics, Cancer Care, Immune System, Clinical Candidate, Tumor Killing, Immunosuppression, Toxicity, Solid Tumors, Antibody Development, Cancer Immunotherapies, Biolojic Design, ATP Funding

Frequently Asked Questions

Companies similar to Aulos Bioscience include Merus N.V., Surface Oncology Inc., ImmunoBiochem Corporation, Oxford BioTherapeutics, Elevation Oncology. They work in Biotechnology and Health Care and share Aulos Bioscience's focus on immuno-oncology, solid tumors and immune system.
Bounce Watch lists 12 companies that share Aulos Bioscience's industries and are closest to it in business tags, services, target customers, business model and size.
Aulos Bioscience is an immuno-oncology company that aims to revolutionize cancer patient care through its computationally designed IL-2 therapeutics. The company's flagship clinical candidate, AU-007, has been engineered to leverage a patient's own IL-2 to induce tumor killing while minimizing associated toxicities. Fo...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Aulos Bioscience: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at Aulos Bioscience on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout